Make that four drug approvals for Pfizer’s oncology unit in less than two months. In a welcome streak for the pharma giant—what with Lyrica generics looming—the FDA handed out a go-ahead for Daurismo, a treatment for acute myeloid leukemia. More:
read moreAfter winning European approval for its gene therapy Luxturna, Novartis is working on individual reimbursement plans with member countries. The drugmaker expects to finalize the deals in 2019 and 2020. More: Novartis plots 'innovative' payment models for pricey Luxturna's EU
read moreHow much are drugmakers willing to pay for a faster trip to market in the U.K.? A cap of 2% on branded-drug sales growth should do. The catch: That cap actually tops annual growth over the past five years, but
read moreAbbVie and Roche’s Venclexta is leaving familiar territory with its latest approval, and it won’t be an easy land grab. To establish itself on its new turf, the blood cancer drug will have to duke it out with some Big
read moreNew research from Roche UK has revealed that 82% of Generation Z, the age group encompassing 16 to 24 year olds, want to see the NHS introduce digital solutions to better manage their health and improve care. More: Generation Z
read moreThe Cell and Gene Therapy (CGT) Catapult has launched the first Advanced Therapy Medicinal Products (ATMP) focused apprenticeship programme, developed in partnership with The Medicine Manufacturing Industry Partnership (MMIP). More: Cell and Gene Therapy Catapult addresses sector skills gap Source:
read more© 1994 - 2026 B.M. Pharmaceuticals